Mesoblast share price on the rise after delivering promising FY20 results

The Mesoblast share price is on the rise this morning after the company delivered positive FY20 results and sets itself up for FY21.

| More on:
drug capsule opening up to reveal dollar signs signifying rising asx share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The share price of ASX junior biotechnology company Mesoblast Limited (ASX:MSB) is on the move after the company released its FY20 results to the market Thursday morning. At the time of writing, the Mesoblast share price had risen 3.69% to $5.34.

What's moving the Mesoblast share price?

The Mesoblast share price has been boosted after the company reported a 92% increase in revenues to US$32.2 million, while its loss after tax decreased by 13% year on year to US$77.9 million. Despite posting a loss for the year, the company has a strong balance sheet, with US$129.3 million in cash on hand as at 30 June 2020. Most of this came courtesy of a successful US$90 million institutional capital raise in May.

However, most investors will be focused on the company's FY20 operational highlights and how it is setting itself up to deliver in FY21. Mesoblast has a number of its stem cell treatments in final trial and approval phases, the most exciting of which is its flagship product, Ryoncil.

Ryoncil can be used to treat graft versus host disease (GvHD). GvHD is a potentially life-threatening complication which can occur in cancer patients who have received bone marrow transplants. In some of these cases, the donated 'graft' cells can attack the patient's own body cells. 

Earlier this month, the Oncological Drugs Advisory Committee (ODAC), which advises the United States Food and Drug Administration (FDA), voted in favour of the efficacy and safety of Ryoncil for use in children under 12, sending the Mesoblast share price higher. There are currently no FDA-approved treatments for GvHD patients in this age group.

The license application for Ryoncil is now under priority review with the FDA, with the potential for it to be approved by 30 September 2020. Mesoblast is hopeful that it can launch Ryoncil in the US during the December quarter. The company sees this as a significant commercial opportunity.

Another exciting application that could drive the Mesoblast share price is its product's possible treatment of COVID-19 induced acute respiratory distress syndrome (ARDS). A recent pilot study delivered promising results, and a phase 3 clinical trial involving up to 30 leading medical centres across the US could go ahead next quarter, pending a review of safety and efficacy data by the US Data Safety Monitoring Board.

Should you invest?

There are always significant risks involved with investing in a junior healthcare company like Mesoblast. There is still the real possibility Ryoncil won't get the requisite approvals from the FDA, or that the ARDS phase 3 trials won't go head. While early promising results make these outcomes unlikely, they are still possible.

And investors can see the potentially volatile effects of either of these outcomes on the Mesoblast share price. In early August, Mesoblast shares plummeted 37% to just $3.07 in the space of two days, before shooting back up again by almost 70%. These big swings occurred either side of the positive ODAC announcement and show just how heavily the company's valuation rests on these approvals.

Mesoblast is an exciting company which is setting itself up to deliver a potential banner year in FY21. However, given its recent share price performance it might not all be smooth sailing. So, be prepared for some short-term bumps along the way if you do choose to invest in today's Mesoblast share price.

Motley Fool contributor Rhys Brock has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »